期刊文献+

铂类抗肿瘤药物甲啶铂的水合反应研究 被引量:2

The Study of Aquation of Picoplatin,a Platinum-based Anti-tumor Drug
暂未订购
导出
摘要 采用高效液相色谱研究了抗肿瘤药物甲啶铂的水合反应,以及甲啶铂在0.9%NaCl溶液中的稳定性。结果表明,甲啶铂的水合反应遵循一级反应动力学规律,20℃时反应速率常数为k=0.03086h-1,半衰期22.5 h,反应活化能E=80.6 kJ/mol;在0.9%NaCl溶液中,甲啶铂的水合反应被抑制,反应达到平衡后,甲啶铂的降解不超过4%。 HPLC analytical method was used to investigate the aquation of picoplatin, and the stability of picoplatin in 0.9% NaC1 solution. The results show that the aquation of picoplatin followed the law of the first-order reaction, the rate constant was 0.03086 h^-1, the half life period was 22.5 h, the activation energy was 80.6 kJ/mol. Picoplatin is stable in 0.9% NaC1 solution, the degradation did not exceed 4% when the reaction achieved balance.
出处 《贵金属》 CAS CSCD 北大核心 2014年第3期10-13,共4页 Precious Metals
基金 云南省科技厅重点新产品开发计划“抗肿瘤化学I类新药甲啶铂注射液的临床前预研究”(2013BC010)
关键词 药物化学 抗肿瘤药物 甲啶铂 水合反应 一级反应 medicinal chemistry platinum-based anti-tumor drug picoplatin aquation the first-orderreaction
  • 相关文献

参考文献6

二级参考文献14

  • 1刘伟平,普绍平,杨一昆,熊惠周.电导法测定铂抗癌药物的解离速率[J].贵金属,1996,17(3):28-30. 被引量:4
  • 2DOUILLARD JY, SCHILLER J. ZD0473 combined with other chemotherapeutic agent for the treatment of solid malignancies [ J ]. Eur J Cancer, 2002,38(Suppl) : S25 -S31.
  • 3GORA ME, ATKINSON R J, THOMAS H, et al. ZD0473 in platinum-pretreated ovarian cancer[J]. Eur J Cancer, 2002,38 ( Suppl) : S2416 - S2420.
  • 4TREAT J, SCHILLER J, QUOIX E, et al. ZD0473 treatment in lung cancer: an overview of the clinical trial results[J]. Eur J Cancer, 2002,38(Suppl) : S13 - S18.
  • 5普绍平,丛艳伟,何键,等.甲啶铂的提纯:中国,200810058602.7[P].2008-06-30.
  • 6国家药典委员会.《中国人民共和国药典》[S].二部.北京:化学工业出版社,2005:凡例,XIII-XIV.
  • 7GERALDINE M, SIMON P, PETER JS. Contrasting chemistry of cis- and trans-platinum (II) diamine anticancer compound : hydrolysis studies of picoline complexes [J]. Inorg Chem, 2005, 44 (21) : 7459 -7467.
  • 8XU Qing(许青)Guowai Yiyao(World Pharmacy),2000,21(2),99.
  • 9SUN Yan(孙燕),GUAN Zhong-Zhen(管忠震),JIN MaoLin(金懋林).Li Wei-Lian(李维廉)Aizheng(Chinese J.of Cancer),1999,18(3),237.
  • 10LIU Zhu-Dong(刘祝东),PU Shao-Ping(普绍平),GAO Wen-Gui(高文桂),YU Yao(余尧)Youse Jinshu( Noferrous Metals), 2002, 54, suppl.,355.

共引文献11

同被引文献14

  • 1KOMEDA S, CASINI A. Next -generation anticancer metallo- drugs[J]. Curt Top Med Chem,2012,12(3):219.
  • 2ROSENBERG B, VANCAMP L. Platinum compounds:a new class of potent antitamour agents [J]. Nature, 1969,222:385.
  • 3WAGSTAFF A J, WARD A, BENFIELD P, et al. Carboplatin [J]. Drugs, 1989,37 (2) :162.
  • 4WHEATE NJ, WALKER S, CRAIG GE, et al. The status of plati- num anticancer drugs in the clinic and in clinical trials[ J]. Dal- ton T, 2010,39(35) :8113.
  • 5LEBWOHL D, CANETYA R. Clinical development of platinum complexes in cancer therapy : an historical perspective and an up- date[J]. Eur J Cancer,1998,34(10) :1522.
  • 6BARNARD CFJ. Platinum anti -cancer agents; twenty years of continuing development [ J ]. Platinum Metals Rev, 1989,33 : 162.
  • 7CERESA C,BRAVIN A,CAVALE'ITI G,et al. The combined thera- peutical effect of metal - based drugs and radiation therapy: the present status of research[J]. Curt Med Chem,2014,21 (20) :2237.
  • 8PINATO O, MUSETTI C, FARRELL NP, ct al. Platinum - based drugs and proteins:reactivity and relevance to DNA adduct for- mation[ J]. J Inorg Biochem,2013 ,122 :27.
  • 9HEIDEL JD,DAVIS ME. Clinical developments in nanotechnolo- gy for cancer therapy [ J ]. Pharm Res,2011,28 (2) : 187.
  • 10BOULIKAS T,PANTOS A,BELLIS E,et al. Designing platinum compounds in cancer:structures and mechanisms [ J ]. Cancer T- her,2007,5:537.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部